Menu Search
Equities

Genomtec SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4VI:FRA

Genomtec SA

Actions
  • Price (EUR)1.01
  • Today's Change-0.012 / -1.17%
  • Shares traded2.00k
  • 1 Year change-35.90%
  • Beta-0.0029
Data delayed at least 15 minutes, as of Feb 10 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Genomtec SA is a Poland-based company engaged in biotechnology and medical research business sector and it is operating in the field of clinical diagnostics. The Company is focused on development of of Genomtec ID, a mobile platform for genetic diagnosis in the point of patient care. Its creation and commercialization allows the diagnostic process to be executed in point of care setting, such as: primary care clinics, pharmacies, doctor’s offices, hospital emergency departments (ERs) without the need for complicated and time-consuming laboratory workflow conducted by qualified personnel.

  • Revenue in PLN (TTM)15.00k
  • Net income in PLN-11.01m
  • Incorporated2017
  • Employees--
  • Location
    Genomtec SAWroclawski Park Biznesu 3ul. Bierutowska 57-59WROCLAW 51-317PolandPOL
  • Websitehttps://genomtec.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.